PH12021550054A1 - Variants of cd38 antibody and uses thereof - Google Patents

Variants of cd38 antibody and uses thereof

Info

Publication number
PH12021550054A1
PH12021550054A1 PH12021550054A PH12021550054A PH12021550054A1 PH 12021550054 A1 PH12021550054 A1 PH 12021550054A1 PH 12021550054 A PH12021550054 A PH 12021550054A PH 12021550054 A PH12021550054 A PH 12021550054A PH 12021550054 A1 PH12021550054 A1 PH 12021550054A1
Authority
PH
Philippines
Prior art keywords
variants
antibody
amino acid
acid residues
mutations
Prior art date
Application number
PH12021550054A
Other languages
English (en)
Inventor
Goeij Bart E C G De
Grietje Andringa
Frank Beurskens
Janine Schuurman
David Satijn
Tahamtan Ahmadi
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of PH12021550054A1 publication Critical patent/PH12021550054A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PH12021550054A 2018-07-13 2021-01-08 Variants of cd38 antibody and uses thereof PH12021550054A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697730P 2018-07-13 2018-07-13
US201962848874P 2019-05-16 2019-05-16
PCT/EP2019/069028 WO2020012036A1 (en) 2018-07-13 2019-07-15 Variants of cd38 antibody and uses thereof

Publications (1)

Publication Number Publication Date
PH12021550054A1 true PH12021550054A1 (en) 2021-09-27

Family

ID=67396922

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550054A PH12021550054A1 (en) 2018-07-13 2021-01-08 Variants of cd38 antibody and uses thereof

Country Status (22)

Country Link
US (3) US20200017600A1 (https=)
EP (1) EP3820900A1 (https=)
JP (2) JP7526717B2 (https=)
KR (1) KR20210031932A (https=)
CN (2) CN112513082B (https=)
AU (1) AU2019300223A1 (https=)
BR (1) BR112020026432A2 (https=)
CA (1) CA3106146A1 (https=)
CL (1) CL2021000066A1 (https=)
CO (1) CO2021001544A2 (https=)
CR (1) CR20210081A (https=)
DO (2) DOP2021000006A (https=)
EC (1) ECSP21010092A (https=)
IL (1) IL279937A (https=)
MA (1) MA53122A (https=)
MX (1) MX2020013631A (https=)
MY (1) MY205398A (https=)
PE (1) PE20211858A1 (https=)
PH (1) PH12021550054A1 (https=)
SG (1) SG11202012993SA (https=)
TW (1) TW202019518A (https=)
WO (1) WO2020012036A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
US20200017600A1 (en) * 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
US20230272105A1 (en) * 2020-01-16 2023-08-31 Genmab A/S Formulations of cd38 antibodies and uses thereof
JP2023529846A (ja) * 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
WO2023044346A2 (en) 2021-09-14 2023-03-23 Ausper Biopharma Co., Ltd. Vaccines for coronavirus prevention and treatment
US20240400711A1 (en) * 2021-09-23 2024-12-05 Sound Biopharmaceuticals Co. Ltd. Cd38 monoclonal antibody and application thereof
AU2022380155A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
CN114409788B (zh) * 2022-03-04 2022-10-04 四川大学华西医院 抗cd38的抗体及其应用
TW202432177A (zh) 2022-10-31 2024-08-16 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體及其用途
WO2024131849A1 (zh) * 2022-12-21 2024-06-27 非同（成都）生物科技有限公司 Cd38单克隆抗体及其应用
AU2024239150A1 (en) * 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
CN120965865B (zh) * 2025-10-15 2026-01-16 内蒙古盛健生物科技有限责任公司 一种用于特异性治疗奶山羊羔羊口疮的抗体及其应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US835A (en) 1838-07-12 X i i i x
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
SMT202000031T1 (it) * 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
JP6454547B2 (ja) * 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
BR112015022855A2 (pt) 2013-03-14 2017-11-07 Shire Human Genetic Therapies composições e método para produção de um anticorpo in vitro
EP3388834B1 (en) 2013-03-15 2020-04-15 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
US9862752B2 (en) * 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
EP4667492A3 (en) * 2015-05-26 2026-04-15 Ramot at Tel-Aviv University Ltd. Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
EA037548B1 (ru) 2015-06-24 2021-04-12 Янссен Байотек, Инк. Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
CN109476737A (zh) * 2015-12-01 2019-03-15 根马布有限公司 抗dr5抗体及其使用方法
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN109563511A (zh) 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
KR102317884B1 (ko) 2016-12-21 2021-10-26 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작
CN117887794A (zh) 2016-12-21 2024-04-16 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
US20200017600A1 (en) * 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof

Also Published As

Publication number Publication date
US20240317881A1 (en) 2024-09-26
JP7526717B2 (ja) 2024-08-01
AU2019300223A1 (en) 2021-01-07
ECSP21010092A (es) 2021-03-31
MA53122A (fr) 2021-05-19
MX2020013631A (es) 2021-03-25
IL279937A (en) 2021-03-01
KR20210031932A (ko) 2021-03-23
SG11202012993SA (en) 2021-02-25
JP2021524276A (ja) 2021-09-13
CR20210081A (es) 2021-06-24
DOP2024000217A (es) 2024-11-29
JP2024075737A (ja) 2024-06-04
US20200017600A1 (en) 2020-01-16
MY205398A (en) 2024-10-19
DOP2021000006A (es) 2021-03-15
WO2020012036A1 (en) 2020-01-16
CA3106146A1 (en) 2020-01-16
PE20211858A1 (es) 2021-09-21
CN112513082A (zh) 2021-03-16
BR112020026432A2 (pt) 2021-03-23
CN112513082B (zh) 2025-08-12
TW202019518A (zh) 2020-06-01
CL2021000066A1 (es) 2021-05-28
EP3820900A1 (en) 2021-05-19
CN120865412A (zh) 2025-10-31
CO2021001544A2 (es) 2021-03-08
US20200165352A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
PH12021550054A1 (en) Variants of cd38 antibody and uses thereof
PH12020552232A1 (en) IL-11 Antibodies
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MY202516A (en) Antibodies to tigit
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
MX2023000334A (es) Anticuerpos anti-trem2 y metodos de uso de los mismos.
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
EP4219689A3 (en) Immune effector cell therapies with enhanced efficacy
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX383543B (es) Anticuerpo anti-calicreina-2 humanizado.
PH12017502019B1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
WO2016086189A3 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
NZ755083A (en) Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
MY157948A (en) Humanized anti-factor d antibodies
PH12013500990A1 (en) Neutralizing anti-ccl20 antibodies
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
PH12017500201A1 (en) NOVEL ANTI-HUMAN Ig� ANTIBODY
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
FI3057992T3 (fi) Ihmisvasta-aine aggrekanaasityyppisiä ADAMTS-lajeja vastaan aggrekanaasiin liittyvien tautien terapeutiikkaan
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
EA202190268A1 (ru) Варианты антитела против cd38 и их применение
WO2020033925A3 (en) Antibodies that bind cd277 and uses thereof